Access is Broken Originally posted on obesity.news  on March 3th, 2026 Big shifts are happening in the GLP-1 world. This week on On The Pen , we break down new federal action targeting pharmacy middlemen, potential FDA moves that could impact compounded semaglutide, and the rise of cash-pay weight loss clinics from companies like Walgreens and Amazon. If you’re navigating GLP-1 access, insurance denials, compounding changes, or wondering where this all heads next — this episode connects the...

Predictions and a Little Bathroom Humor Originally posted on obesity.news on January 20th, 2026 This episode isn’t really about OTC GLP-1s, it’s about pattern recognition. After 3 solid years studying this industry, Dave recognizes the early signals: deals are made, pharma speaks, regulation moves, and patients benefit. The Zepbound vial story serves as context. It’s less “I told you so” and more “this is how these shifts actually happen.” What’s changing isn’t just access, it’s tone. The...

FDA Reversals, Pharma Momentum, and Why Patients Can’t Afford to Be Silent Originally posted on obesity.news on January 13th, 2026 GLP-1, Maritide, and Oprah, A Week That Felt Different at OTP A lot happened in the broader GLP-1 world this week, but what stood out to me wasn’t just the headlines. It was how Dave kept returning to the same core question on air: what does this actually mean for patients? Whether he was reacting to regulatory shifts, pharma claims, or mainstream voices...